NCT04314362View on ClinicalTrials.gov

Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

January 6, 2021

Study Completion Date

January 6, 2021

Conditions

Meibomian Gland Dysfunction

Interventions

DRUG

AZR-MD-001 ointment/semi-solid drug

AZR-MD-001 (1.0%) and suitable excipient

Trial Locations (1)

Unknown

Fiona Stapleton, Sydney

Sponsors

Lead Sponsor

Azura Ophthalmics

All Listed Sponsors

collaborator

The University of New South Wales

OTHER

lead

Azura Ophthalmics

INDUSTRY

NCT04314362 - Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD) | Biotech Hunter | Biotech Hunter